Analysis Tools
mortality/aging
|
• most females that develop lymphomas die at about 9 weeks post-4OHT injection
• all mutants die from tumor burden by 45 weeks post-4OHT injection
|
neoplasm
|
• treatment of mice with 4OHT at 6 weeks of age to induce cre-mediated recombination results in tumor formation with a mean latency of 17 weeks
• multiple tumors are seen in 27.3% of 4OHT-treated mice
• 46.1% of females develop endometrial cancer after 4OHT treatment
|
 |
• 35% of males develop intestinal cancer after 4OHT treatment, arising from the colorectum and small intestine
|
|
• 76.9% incidence of lymphomas in females after 4OHT treatment
• 40% incidence of lymphomas in males after 4OHT treatment
• lymphomas mainly arise from the thymus and mesenteric lymph nodes
• all lymphomas are derived from CD3+ T-cells with either a mature appearance of small lymphocytes or large lymphoblasts
|
|
|
• 20% of males develop prostate cancer after 4OHT treatment
|
|
|
• prostate intraepithelial neoplasm (PIN) is observed at 4-6 weeks post 4-OHT treatment
|
|
• about 50% of males and females exhibit malignant tumors at 21 weeks and 10-11 weeks after 4OHT treatment, respectively
|
|
• 10% of males and 15.4% of females develop squamous cell carcinoma of the epidermis after 4OHT treatment
|
digestive/alimentary system
|
• males develop small or large intestinal polyps at more than 35 weeks post 4OHT treatment
|
|
|
• 35% of males develop intestinal cancer after 4OHT treatment, arising from the colorectum and small intestine
|
endocrine/exocrine glands
|
• 76.9% incidence of lymphomas in females after 4OHT treatment
• 40% incidence of lymphomas in males after 4OHT treatment
• lymphomas mainly arise from the thymus and mesenteric lymph nodes
• all lymphomas are derived from CD3+ T-cells with either a mature appearance of small lymphocytes or large lymphoblasts
|
|
|
• prostate hyperplasia is observed at 4-6 weeks post 4-OHT treatment
|
|
|
• 20% of males develop prostate cancer after 4OHT treatment
|
|
|
• prostate intraepithelial neoplasm (PIN) is observed at 4-6 weeks post 4-OHT treatment
|
reproductive system
|
|
• prostate hyperplasia is observed at 4-6 weeks post 4-OHT treatment
|
|
|
• 20% of males develop prostate cancer after 4OHT treatment
|
|
|
• prostate intraepithelial neoplasm (PIN) is observed at 4-6 weeks post 4-OHT treatment
|
 |
• most females develop endometrial hyperplasia at between 7 and 9 weeks post 4-OHT treatment
|
integument
|
• 10% of males and 15.4% of females develop squamous cell carcinoma of the epidermis after 4OHT treatment
|
homeostasis/metabolism
|
• about 50% of males and females exhibit malignant tumors at 21 weeks and 10-11 weeks after 4OHT treatment, respectively
|
immune system
|
• 76.9% incidence of lymphomas in females after 4OHT treatment
• 40% incidence of lymphomas in males after 4OHT treatment
• lymphomas mainly arise from the thymus and mesenteric lymph nodes
• all lymphomas are derived from CD3+ T-cells with either a mature appearance of small lymphocytes or large lymphoblasts
|
hematopoietic system
|
• 76.9% incidence of lymphomas in females after 4OHT treatment
• 40% incidence of lymphomas in males after 4OHT treatment
• lymphomas mainly arise from the thymus and mesenteric lymph nodes
• all lymphomas are derived from CD3+ T-cells with either a mature appearance of small lymphocytes or large lymphoblasts
|
